Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped down before the market opened on Monday . The stock had previously closed at $19.00, but opened at $18.30. Ascentage Pharma Group International shares last traded at $18.15, with a volume of 1,128 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. B. Riley Financial began coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 target price on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 price target for the company. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Finally, BTIG Research reissued a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. Based on data from MarketBeat.com, Ascentage Pharma Group International currently has an average rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Price Performance

The firm’s 50 day moving average price is $18.15 and its two-hundred day moving average price is $21.43. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of hedge funds and other institutional investors have recently bought and sold shares of AAPG. UBS Group AG grew its position in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares in the last quarter. Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International during the 2nd quarter valued at about $391,000. Finally, Citadel Advisors LLC purchased a new position in Ascentage Pharma Group International during the 3rd quarter valued at about $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.